Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode.
- 03/27/2025
|
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
- SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023.
- 03/27/2025
|
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
- SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 03/13/2025
|
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
- SALT LAKE CITY , March 6, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 4, 2025, the Securities & Governance Litigation Team at BakerHostetler, the legal firm retained to represent the Company, won complete dismissal on summary judgment of a Section 10(b) securities class action that had been pending against the Company in the United States District Court for the District of Utah. See Gelt Trading, Ltd.
- 03/06/2025
|
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
- The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India SALT LAKE CITY , March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will be hosting a symposium to honor International HPV (human papillomavirus) Awareness Day 2025.
- 03/03/2025
|
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
- On Friday, Co-Diagnostics, Inc. CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance.
- 02/24/2025
|
Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025
- SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025. Live from MarketSite is Nasdaq's flagship broadcast opportunity, showcasing innovative leaders and disruptive companies in their fields.
- 01/07/2025
|
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
- New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders SALT LAKE CITY , Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt.
- 12/10/2024
|
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C.
- 11/07/2024
|
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates
- Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.20 per share a year ago.
- 11/07/2024
|
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results
- SALT LAKE CITY , Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results: Revenue of $0.6 million, which declined from $2.5 million during the prior year primarily due to timing of grant revenue recognition.
- 11/07/2024
|
Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024
- SALT LAKE CITY , Nov. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth and delivering a presentation at the MEDICA 2024 trade fair in Düsseldorf, Germany on November 11-14. MEDICA has become the largest medical B2B trade fair in the world, attracting 83,000 visitors and over 5,300 exhibitors from almost 70 countries.
- 11/05/2024
|
Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast
- SALT LAKE CITY , Oct. 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2024 results on Thursday, November 7, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 10/25/2024
|
Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024
- SALT LAKE CITY , Oct. 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at Africa Health/Medlab Africa in Cape Town, South Africa on October 22-24, 2024. The conference website describes it as the largest gathering of healthcare companies, technology, products and services in the sub-Saharan region, catering to an audience of distributors, government representatives, laboratory executives, and purchasing/procurement managers from the South African Development Community region and around the world, who attend to meet with world-class suppliers and manufacturers.
- 10/21/2024
|
Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3
- SALT LAKE CITY , Oct. 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo at the Mountain America Expo Center in Sandy, Utah on October 2-3, 2024. The UHCA/UCAL Convention includes sessions and events for executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living and intermediate care facilities, and will include an expo for companies to exhibit their products and services relevant to these industries.
- 10/02/2024
|
Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan
- SALT LAKE CITY , Sept. 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company representatives will be accompanying Utah Governor Cox and the Governor's Office of Economic Opportunity, as part of the latest World Trade Center (WTC) Utah trade mission to South Korea and Japan from September 24-October 5.
- 09/24/2024
|
Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test
- SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test.
- 09/05/2024
|
Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.
- SALT LAKE CITY , Aug. 15, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024.
- 08/15/2024
|
Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Jade Montgomery - H.C. Wainwright Operator Good day, and welcome to the Co-Diagnostics Second Quarter 2024 Earnings Conference Call.
- 08/10/2024
|
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates
- Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.
- 08/08/2024
|
Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results
- SALT LAKE CITY , August 8, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results: Revenue of $2.7 million, up from $0.2 million during the prior year primarily due to the achievement of certain milestones under various grant agreements the company was awarded Operating expenses of $10.1 million decreased by 13.7% from the prior year due to lower stock-based compensation expense, bad debt expense, and expenses related to clinical trials for the Co-Dx PCR platform Operating loss of $7.7 million compared to operating loss of $12.0 million in 2023 Net loss of $7.6 million, compared to net loss of $8.9 million in the prior year, representing a loss of $0.25 per fully diluted share, compared to a loss of $0.31 per fully diluted share in the prior year Adjusted EBITDA loss of $5.9 million compared to $9.6 million in the prior year Cash, cash equivalents, and marketable securities of $44.9 million as of June 30, 2024 Second Quarter and Recent 2024 Business Highlights: Submitted first 510(k) application to the U.S. Food and Drug Administration (FDA) for the Co-Dx™ PCR Pro™ Platform, which includes the Co-Dx PCR Pro instrument and the Co-Dx PCR COVID-19 test for over-the-counter (OTC) use Inaugurated a new manufacturing facility in South Salt Lake to manufacture our patented Co-Primers® oligonucleotides, the Co-Dx™ PCR Pro™ instrument, and test cups for the new Co-Dx PCR platform Expanded Co-Dx vector control technology to a 15th U.S. state, Nevada, which includes Vector Smart® PCR tests in environmental surveillance of mosquito pools for mosquito-borne illnesses Attended and participated in the FIME 2024 trade show in Miami Beach, Florida, which included exhibitors from 116 countries and over 15,000 professional attendees, to display the new Co-Dx PCR platform "We are very pleased by the progress Co-Diagnostics has made so far this year," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.
- 08/08/2024
|
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago
- SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024, in Chicago, IL. Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-of-care Co-Dx™ PCR platform* in closing the global diagnostics gap for an array of potential indications, including tuberculosis (TB).
- 07/29/2024
|
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast
- SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 07/25/2024
|
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States
- SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week. Co-Dx vector control technology includes Vector Smart® PCR tests used in environmental (non-diagnostic) surveillance of mosquito pools for mosquito-borne illnesses like West Nile virus, Zika, dengue and chikungunya.
- 07/02/2024
|
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
- SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21. FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relationships, and for strengthening business ties with the global medical device and equipment market, with exhibitors from 116 countries and more than 15,000 expected professional attendees.
- 06/18/2024
|
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform
- The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY , June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use. Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received.
- 06/14/2024
|
Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
- 05/09/2024
|
Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
- SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: Revenue of $0.5 million, down from $0.6 million during the prior year.
- 05/09/2024
|
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
- SALT LAKE CITY , April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 04/25/2024
|
Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan
- SALT LAKE CITY , April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference (APRC) of the International Union Against Tuberculosis and Lung Disease on April 26-29, 2024 in Taipei, Taiwan. The theme for the 2024 conference is "Shaping a Safer World Through High-Quality Holistic Healthcare," reflecting the organizers' vision to discuss current evidence, share ideas and information, and accelerate innovation.
- 04/24/2024
|
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
- Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY , April 12, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it held the ribbon cutting event for its new manufacturing facility yesterday in the City of South Salt Lake. The facility has been designed to manufacture the Co-Dx Pro™ instrument and test cups for the new platform*, as well as the Company's patented Co-Primers™ chemistry that underpins the Company's PCR diagnostic tests.
- 04/12/2024
|
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
- SALT LAKE CITY , April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Company, Richard Abbott (President) served as the President of Advanced Conceptions, Inc., a wholly-owned subsidiary of Co-Diagnostics since December 2021, and has been instrumental in establishing the teams and technology of the Co-Dx PCR platform*.
- 04/04/2024
|
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address
- Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY, March 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address at the 5th Annual MarketsandMarkets conference in London, Company CEO Dwight Egan shared an update on the new manufacturing facilities in Salt Lake City, Utah and in Ranoli, India, including announcing the grand opening of the new Utah facility next month. Both Co-Dx and CoSara Diagnostics, the Company's joint venture for manufacturing in India, will be manufacturing the Co-Dx™ PCR Pro™ instrument and Co-Dx PCR test cups that run on the Company's new PCR platform*.
- 03/21/2024
|
Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England
- SALT LAKE CITY, Utah , March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, England. Mr. Egan will be delivering the keynote presentation at 9:00 am local time on March 21, and will be discussing impacts that the Company's upcoming Co-Dx PCR platform* is anticipated to have on the future of diagnostics accessibility.
- 03/18/2024
|
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
- 03/14/2024
|
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
- SALT LAKE CITY , March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full Year 2023 Financial Results: Revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart® COVID-19 tests.
- 03/14/2024
|
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
- The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B. CoSara's new real-time multiplex PCR test is built on the Company's patented Co-Primers™ technology and designed to simultaneously detect influenza A (H1N1, H3N2, H7N9, H1N2, H5N1, H2N2, H9N2, H10N8, H5N6, H7N7, H7N4, H7N2 and H2N1), influenza B (Yamagata and Victoria strains) and to differentiate between H1N1 and H3N2.
- 03/07/2024
|
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast
- SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2023 financial results on Thursday, March 14, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 02/29/2024
|
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024
- SALT LAKE CITY , Feb. 1, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the list of events it has chosen to exhibit at or participate in during February, 2024, and which strategically align with the Company's vision. At each event, Co-Dx will discuss its upcoming at-home and point-of-care Co-Dx™ PCR platform technology*, which has been designed to bring PCR diagnostics to the point-of-care in the service of achieving the Company's mission of increasing accessibility of affordable gold-standard PCR diagnostics around the world.
- 02/01/2024
|
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro
- The Company's Emergency Use Authorization submission is for the new Co-Dx PCR Pro instrument and COVID-19 test kit, designed for point-of-care and at-home. The menu of tests in development for the platform includes TB, HPV, and a multiplex respiratory panel for flu A/B, COVID-19, and RSV SALT LAKE CITY , Dec. 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted its Co-Dx™ PCR COVID-19 test with Co-Dx PCR Pro™ instrument for review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).
- 12/27/2023
|
Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Hello. Welcome to the Co-Diagnostics Third Quarter 2023 Earnings Conference Call.
- 11/09/2023
|
Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development
- Company to use funds awarded by the Bill & Melinda Gates Foundation toward the tuberculosis test for its Co-Dx™ PCR platform SALT LAKE CITY , Nov. 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis (TB) test in development, designed to be run on the upcoming Co-Dx™ PCR platform*. The amount awarded is $8.976 million.
- 11/02/2023
|
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023
- SALT LAKE CITY , Oct. 31, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the list of events it has chosen to exhibit at or attend during November, 2023, which strategically align with its mission of increasing accessibility of affordable gold-standard PCR diagnostics around the world. At each event, the Company will discuss its upcoming at-home and point-of-care Co-Dx™ PCR platform technology*, which has been designed to bring PCR diagnostics to the point-of-care as the world adjusts to a post-pandemic diagnostics landscape.
- 10/31/2023
|
Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast
- SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2023 results on Thursday, November 9, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 10/26/2023
|
Co-Diagnostics, Inc. to Host Booth at CASMET Symposium October 23-25
- SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at the Caribbean Association of Medical Technologies (CASMET) Scientific Symposium and BGM, held in Barbados October 22-26, 2023. CASMET is an independent, non-governmental organization representing more than 1500 medical laboratory professionals across the Caribbean basin, a diverse region with needs that the Company believes align with its mission of increasing accessibility of affordable, high-quality diagnostics to markets where they are in greatest demand.
- 10/23/2023
|
Sustainable Infrastructure Dividend ETF Distributions
- TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Middlefield Sustainable Infrastructure Dividend ETF (TSX: MINF) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2023 will be payable to unitholders of Middlefield Sustainable Infrastructure Dividend ETF as follows:
- 10/23/2023
|
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
- Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.10 per share a year ago.
- 08/10/2023
|
Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast
- SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2023 results on Thursday, August 10, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 07/27/2023
|
Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Theodore O'Neill - Litchfield Hills Research Operator Good afternoon and welcome to the Co-Diagnostics' First Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded today.
- 05/11/2023
|
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
- Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.26 per share a year ago.
- 05/11/2023
|
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
- Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/16/2023
|
Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, President and Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Theodore O'Neill - Litchfield Hills Research Operator Good afternoon, and welcome to the Co-Diagnostics, Inc. Fourth Quarter and Full Year 2022 Earnings Results Conference Call.
- 03/16/2023
|
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST
- SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2022 results on Thursday, March 16, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 03/09/2023
|
Co-Diagnostics, Inc. to Present and Host Booth at TRI-CON in San Diego, CA, March 6-8
- SALT LAKE CITY , March 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 30th Molecular and Precision Med TRI-CON ("TRI-CON"), held virtually and in person March 6-8, 2023, in San Diego, CA. Co-Dx, which is also one of two Premier Sponsors of the event, will also be delivering the Lunch Presentation on Monday, March 6 at 11:55 am, focusing on its upcoming at-home/POCT Co-Dx PCR Home™ platform for which the initiation of clinical evaluations was recently announced.
- 03/02/2023
|
Co-Diagnostics ends 3Q with $86.5M in cash; makes significant progress on its Co-Dx PCR Home platform
- Co-Diagnostics Inc (NASDAQ:CODX) posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further advance its Co-Dx PCR Home testing platform for infectious diseases. As of September 30, 2022, the Salt Lake City, Utah-based molecular diagnostics company, had cash, equivalents, and marketable securities of $86.5 million.
- 11/11/2022
|
Co-Diagnostics, Inc. (CODX) Q3 2022 Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Dan Bohrer - VP, Finance and Accounting Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Theodore O'Neill - Litchfield Hills Research Operator Good afternoon, and welcome to the Co-Diagnostics, Inc. Third Quarter 2022 Earnings Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 11/10/2022
|
Co-Diagnostics appoints veteran molecular biologist Mark Poritz as its new chief scientific officer
- Co-Diagnostics Inc (NASDAQ:CODX) has announced the appointment of Mark Poritz as the company's new chief scientific officer (CSO). Poritz is a Harvard University-educated molecular biologist with more than 30 years of experience in the application of polymerase chain reaction (PCR) and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection.
- 11/01/2022
|
CO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
- SALT LAKE CITY , Oct. 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2022 results on Thursday, November 10, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 10/27/2022
|
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic's Over'
- As people acclimatize to the new normal, it's time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.
- 09/27/2022
|
Why Co-Diagnostics Stock Slipped Today
- Investors continued to avoid the company after its big second-quarter whiffs.
- 08/15/2022
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q2 2022 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, President and Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Robert Burns - H.C. Wainwright & Co., LLC James Sidoti - Sidoti & Company, LLC Theodore O'Neill - Litchfield Hills Research, LLC Operator Good afternoon, and welcome to the Co-Diagnostics' Second Quarter 2022 Earnings Conference Call.
- 08/11/2022
|
CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
- CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -166.67% and 75.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
Co-Diagnostics ends 2Q with $96M in cash, expands infectious disease testing menu to include monkeypox
- Co-Diagnostics Inc (NASDAQ:CODX) ended its second quarter of 2022 with a cash balance of US$96 million to help it progress development of its Co-Dx PCR Home testing platform for infectious diseases. During the three-month period to end June 30, 2022, the company completed the principal design for a monkeypox virus test and shipped testing reagents to its international distributor.
- 08/11/2022
|
Why Shares of Co-Diagnostics Stock Fell 10% on Tuesday
- The stock dropped two days before reporting second-quarter earnings.
- 08/09/2022
|
CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?
- CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 07/26/2022
|
Co-Diagnostics set to expand OEM deal with Bio Molecular Systems at AACC expo
- Co-Diagnostics Inc (NASDAQ:CODX) (Co-Dx) has announced that it will be disclosing the global expansion of its original equipment manufacturer (OEM) agreement with Bio Molecular Systems (BMS) at the company's customer and distributor update today at the American Association for Clinical Chemistry's (AACC) Annual Scientific Meeting & Clinical Lab Expo. The molecular diagnostics firm said the expanded branding and distribution OEM agreement increases Co-Diagnostics' approved sales territories to 193 countries worldwide.
- 07/26/2022
|
Co-Diagnostics, Inc. to Announce Expansion of OEM Agreement with Bio Molecular Systems at AACC
- SALT LAKE CITY , July 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing the original Rotor-Gene Real-Time PCR instrument, with a reputation for expertise in developing innovative, versatile, robust, and easy-to-use products.
- 07/26/2022
|
CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests
- CODX stock is up during early afternoon trading as Co-Diagnostics ships out monkeypox testing reagents to help deal with the outbreak. The post CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests appeared first on InvestorPlace.
- 07/11/2022
|
Why Co-Diagnostics Stock Is Rising Today
- The medical test maker just got its new test for monkeypox out the door for the first time.
- 07/11/2022
|
Co-Diagnostics ships monkeypox virus tests to international distributor to fight multi-country outbreak
- Co-Diagnostics (NASDAQ:CODX) Inc announced it has shipped testing reagents for the monkeypox virus, currently exhibiting a multi-country outbreak, to one of its international distributors. In a statement, the molecular diagnostics company said the products shipped were designed and developed on an expedited basis to meet the demands in the distributor's region.
- 07/11/2022
|
Why Co-Diagnostics Is Running Higher Today
- Investors in the diagnostics and research outfit received a dose of beneficial news today.
- 07/05/2022
|
Co-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference
- SALT LAKE CITY , June 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference, held virtually June 28-29, 2022. The Biodetection Technologies Conference is an internationally recognized meeting for experts in detection & identification of biological threats, which this year plans to address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems.
- 06/28/2022
|
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
- CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 06/24/2022
|
Co-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference
- SALT LAKE CITY , June 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Summer Small Cap Virtual Investor Conference June 15-16, 2022. The presentation will begin at 3:15 p.m.
- 06/15/2022
|
Why Co-Diagnostics Trounced the Market on Thursday
- The company is not monkeying around with the latest possible global health menace.
- 05/26/2022
|
Co-Diagnostics develops principal design work on monkeypox PCR test
- Co-Diagnostics (NASDAQ:CODX) Inc, a molecular diagnostics company, has completed the principal design work on a PCR test for the monkeypox virus, the company announced. Outbreaks of the virus have been reported in roughly 20 countries (primarily in Europe) where it is not endemic, with more than 200 confirmed or suspected infections, according to reporting from Reuters and others.
- 05/26/2022
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q1 2022 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Andrew Benson - Head, IR Dwight Egan - Chairman, CEO & President Brian Brown - CFO & Company Secretary Conference Call Participants Yi Chen - H.C. Wainwright & Co. James Sidoti - Sidoti & Company Theodore O'Neill - Litchfield Hills Research Operator Good day, and welcome to the Co-Diagnostics Inc. First Quarter 2022 Earnings Results Conference Call.
- 05/12/2022
|
CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates
- CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
Co-Diagnostics reports record 1Q revenue as company looks to expand into new markets and innovative molecular diagnostics solutions
- Co-Diagnostics (NASDAQ:CODX) Inc has reported record 1Q revenue as the company says it plans to leverage its strong financial position to fund future growth initiatives. For the quarter ending March 31, 2022, the company reported revenue of $22.7 million, up from $20 million for the same quarter in 2021, which it attributed primarily to sales of its Logix Smart COVID-19 test.
- 05/12/2022
|
CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
- SALT LAKE CITY , April 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2022 results on Thursday, May 12, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 04/28/2022
|
Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)
- CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/26/2022
|
Co-Diagnostics says its CoSara Diagnostics Indian joint venture has received clearance to manufacture and sell its Hepatitis C Viral (HCV) Load Kit as an in vitro diagnostic
- Co-Diagnostics (NASDAQ:CODX) has said that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAQ Hepatitis C (HCV) Viral Load Kit as an in vitro diagnostic (IVD). CoSara's new real-time HCV PCR test is built on the company's patented CoPrimer technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with HCV, a disease with no effective vaccine that leads to nearly 300,000 deaths in 2019 according to the World Health Organization (WHO).
- 04/19/2022
|
Why Co-Diagnostics Stock Tumbled by Nearly 12% Today
- The company released its 2021 earnings, and investors weren't happy with them despite profitability guidance that beat estimates.
- 03/25/2022
|
CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates
- CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/24/2022
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2021 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2021 Results - Earnings Call Transcript
- 03/24/2022
|
Co-Diagnostics clocks up $97.9M in full year 2021 revenue on the strength of Logix Smart COVID-19 test sales
- Co-Diagnostics (NASDAQ:CODX) Inc saw a healthy jump in year-over-year revenue driven by global sales of its Logix Smart COVID-19 tests, according to its latest financial results. The molecular diagnostics company clocked up $97.9 million in full-year 2021 revenue, an increase of $23.3 million over 2020 levels, and adjusted EBITDA of $52.1 million compared to $45.3 million in 2020.
- 03/24/2022
|
Why Co-Diagnostics Stock Is Trading Higher After Hours
- Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher in Thursday's after-hours session after the company reported financial results and issued earnings guidance. Co-Diagnostics reported full year 2021 revenue of $97.89 million, which is up $23.3 million year-over-year.
- 03/24/2022
|
Co-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England
- SALT LAKE CITY , March 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will present at the 3rd Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2022, in London, England. Co-Diagnostics CEO Dwight Egan will be presenting on the Company's YourTest™ PCR at-home/point-of-care testing device to the international audience at 14:00 GMT on March 23rd.
- 03/22/2022
|
Co-Diagnostics adds four new experts to its Scientific Advisory Board
- Co-Diagnostics (NASDAQ:CODX) Inc has beefed up its Scientific Advisory Board with the addition of four new experts. The molecular diagnostics company is welcoming Idaho Technology/BioFire CSO Carl Wittwer, pathology professor Karen Carroll, biotech veteran Noriko Kusukawa and Yale research scientist Anne Wyllie to the board.
- 03/17/2022
|
CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?
- CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/16/2022
|
Why Co-Diagnostics Is Soaring Today
- The diagnostics and research outfit gave investors a dose of good news today.
- 03/15/2022
|
Why Co-Diagnostics Shares Are Trading Higher Today
- Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher Tuesday after the company announced its board authorized a share repurchase program, allowing Co-Diagnostics to repurchase up to $30 million of its common stock. "We believe that the current share price provides us.
- 03/15/2022
|
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 EARNINGS RELEASE DATE AND WEBCAST
- SALT LAKE CITY , March 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2021 results on Thursday, March 24, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 03/14/2022
|
Co-Diagnostics says its joint venture CoSara receives clearance from Indian regulators from Hepatitis B viral load test
- Co-Diagnostics (NASDAQ:CODX) Inc announced that CoSara Diagnostics Private Ltd, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAQ Hepatitis B (HBV) Viral Load Kit as an in vitro diagnostic (IVD). CoSara's new real-time HBV PCR test is built on the company's patented CoPrimer technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with HBV, a disease that leads to more than 800,000 deaths per year, according to the World Health Organization.
- 02/03/2022
|
Co-Diagnostics: Swinging For The Fences
- Seeking Alpha's three ratings metrics have long awarded Co-Diagnostics top grades of "A+".
- 01/24/2022
|
4 Stocks With High Growth Potential
- Choosing U.S.-listed equities that have the characteristics listed below represents an arguably solid starting point when screening the market for potential value opportunities:
- 01/05/2022
|
Co-Diagnostics completes acquisition of Idaho Molecular and Advanced Conception to expand its at-home/point-of-care diagnostic device
- Co-Diagnostics (NASDAQ:CODX) Inc announced that it has completed the acquisition of Idaho Molecular Inc and Advanced Conception Inc to provide the company with all existing and future assets and intellectual property related to its upcoming at-home/point-of-care diagnostic device. The transaction was settled for 4.72 million shares of Co-Diagnostics (NASDAQ:CODX) stock, and additional common warrants totaling 465,000.
- 12/31/2021
|
Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week
- Even with COVID-19 cases rising, the prospects for these stocks remain uncertain.
- 12/31/2021
|
Why Co-Diagnostics Stock Rose 15.8% on Monday
- The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.
- 12/27/2021
|
Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform
- Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does: Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.
- 12/22/2021
|
Co-Diagnostics to acquire Idaho Molecular and Advanced Conception for its at-home/point-of-care platform
- Co-Diagnostics (NASDAQ:CODX) Inc announced that it has signed agreements to acquire Idaho Molecular Inc and Advance Conceptions Inc for the development of its upcoming at-home/point-of-care diagnostic device. The Utah-based company said that the transactions will provide it with all the existing and future assets and intellectual property related to the upcoming platform.
- 12/22/2021
|
Co-Diagnostics signs agreement to acquire Idaho Molecular and Advanced Conception for its at-home/point-of-care platform
- Co-Diagnostics (NASDAQ:CODX) Inc announced that it has signed agreements to acquire Idaho Molecular Inc and Advance Conceptions Inc for the development of its upcoming at-home/point-of-care diagnostic device. The Utah-based company said that the transactions will provide it with all the existing and future assets and intellectual property related to the upcoming platform.
- 12/22/2021
|
7 Stocks to Buy to Hedge Against Omicron Variant Risks
- With the omicron variant presenting uncertainties regarding how governments will react, here are some stocks to buy to counter that risk. The post 7 Stocks to Buy to Hedge Against Omicron Variant Risks appeared first on InvestorPlace.
- 12/13/2021
|
Co-Diagnostics partners with TiiCKER to increase connection with retail investors
- Co-Diagnostics (NASDAQ:CODX) Inc said it has partnered with TiiCKER—a consumer shareholder loyalty platform—to increase its connection to retail investors. The Salt Lake City-based company has teamed up with TiiCKER to reach new and existing investors, verify its shareholders and stock perks, and connect with retail investors interested in learning more about its world-class testing services and technology.
- 12/07/2021
|
Co-Diagnostics Stock Sees Movement After Company Says Products Unaffected By Omicron Variant
- Co-Diagnostics Inc. (NASDAQ:CODX) shares gapped higher Monday, but have since fallen and are now trading lower. The company said today its COVID-19 diagnostics are not affected by the omicron variant.
- 11/29/2021
|
Co-Diagnostics says its suite of coronavirus diagnostics not affected by heavily mutated Omicron variant
- Co-Diagnostics (NASDAQ:CODX) Inc., which has a patented platform for the development of molecular diagnostic tests, revealed that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are expected to interfere with any of its suite of coronavirus (COVID-19) PCR diagnostic assays. The Salt Lake City, Utah-based molecular diagnostics company said that the new coronavirus strain includes more than 50 mutations, over 30 of which are found on the virus's spike protein, the main target of the body's immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility, or ability to evade the body's immune response.
- 11/29/2021
|
Why Co-Diagnostics Shot Almost 8% Higher Today
- The company absolutely crushed analysts' Q3 estimates.
- 11/12/2021
|
Co-Diagnostics (CODX) Stock: Why The Price Increased Today
- The stock price of Co-Diagnostics Inc (NASDAQ: CODX) increased by over 6% pre-market today. This is why it happened.
- 11/12/2021
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2021 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2021 Results - Earnings Call Transcript
- 11/11/2021
|
Co-Diagnostics sees record 3Q revenue of $30.1M on Logix Smart coronavirus test sales
- Co-Diagnostics (NASDAQ:CODX) Inc has announced record third-quarter 2021 revenue of $30.1 million, a 38% year-over-year increase, which the company attributed primarily to sales of its Logix Smart coronavirus (COVID-19) test. Co-Diagnostics (NASDAQ:CODX) also recorded a 67.5% increase in its gross profit for the quarter to $26.8 million, representing 89% of consolidated revenue due to improved product mix as compared to the same period last year.
- 11/11/2021
|
Co-Diagnostics says it will be awarded the 'Innovation Impact Award' at the 2021 BioUtah Life Sciences awards
- Co-Diagnostics (NASDAQ:CODX) Inc has said it will be awarded the 'Innovation Impact Award' at the 2021 BioUtah Life Sciences awards which will be presented on Friday, November 12, 2021, during a virtual ceremony in which pre-recorded videos of the winners will be unveiled. Co-Diagnostics CEO Dwight Egan will accept the award on behalf of the company.
- 11/11/2021
|
Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform
- Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does: Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.
- 11/05/2021
|
Analysts Estimate CoDiagnostics, Inc. (CODX) to Report a Decline in Earnings: What to Look Out for
- CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/04/2021
|
Co-Diagnostics says its Logix Smart COVID-19 test has been approved for sale in the UK
- Co-Diagnostics (NASDAQ:CODX) Inc has announced that its Logix Smart SARS-CoV-2 2-Gene multiplex test is now available for sale in the UK after being validated according to the United Kingdom Health Security Agency's (UKHSA) Medical Devices Regulations 2021 under Coronavirus Test Device Approvals (CTDA). The company said the Logix Smart test is available for sale through Client Life Science, Co-Diagnostics (NASDAQ:CODX)' authorized distributor in the UK.
- 11/04/2021
|
Co-Diagnostics says its CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test
- Co-Diagnostics Inc., revealed that CoSara Diagnostics Pvt Ltd., its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic (IVD).
- 10/06/2021
|
Co-Diagnostics says it CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test
- Co-Diagnostics Inc., revealed that CoSara Diagnostics Pvt Ltd., its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic (IVD).
- 10/06/2021
|
Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for Dengue/Chikungunya Multiplex Test
- SALT LAKE CITY, Oct. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic ("IVD"). The CDSCO approval marks the 10th assay manufactured and sold by CoSara to receive clearance from the CDSCO, and follows the recent clearance of standalone dengue and chikungunya assays last month.
- 10/06/2021
|
Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform
- Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does: Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.
- 09/30/2021
|
Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform for the masses
- Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does: Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.
- 09/30/2021
|
Co-Diagnostics to introduce its upcoming at-home and point-of-care PCR device at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Co-Diagnostics, Inc. has said it will be introducing its upcoming at-home and point-of-care PCR device at a press conference at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo being held September 26-30, 20321, in Atlanta, Georgia.
- 09/27/2021
|
Co-Diagnostics announces corporate rebranding after period of transformative growth and expansion
- Co-Diagnostics Inc. is rebranding its image to better reflect its growing scope, mission, and upcoming expansion into new diagnostics verticals.
- 09/23/2021
|
Co-Diagnostics, Inc. Announces Corporate Rebranding Following Period of Transformative Growth and Expansion
- SALT LAKE CITY, Sept. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following its recent transformative growth, the Company is rebranding its image to better reflect its expanded scope, mission, and upcoming expansion into new diagnostics verticals.
- 09/23/2021
|
Co-Diagnostics says its Logix Smart ABC Test is authorized for use in Mexico
- Co-Diagnostics Inc has announced that its Logix Smart Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology (InDRE) after the department successfully concluded an independent evaluation of the test's sensitivity and specificity for use as an RT-PCR multiplex test in that market. The InDRE, which is comparable to the US Centers for Disease Control and Prevention (CDC), is required to evaluate any test used to detect coronavirus (COVID-19) before the test may gain clearance to be sold into the Mexican healthcare market, Co-Diagnostics said.
- 09/21/2021
|
Co-Diagnostics, Inc. Logix Smart™ ABC Test Authorized for Use in Mexico
- SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology ("InDRE") after InDRE successfully concluded an independent evaluation of the test's sensitivity and specificity for use as an RT-PCR multiplex test in that market.
- 09/21/2021
|
Co-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference
- SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Fall Virtual Investor Conference.
- 09/20/2021
|
Co-Diagnostics says its CoSara JV received regulatory clearance in India for Saragene dengue and chikungunya tests
- Co-Diagnostics (NASDAQ:CODX) Inc has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene dengue and chikungunya RT-PCR tests as in vitro diagnostics (IVD). The Saragene test kits approved by the CDSCO use the company's patented CoPrimer technology for the qualitative detection of these mosquito-borne viruses.
- 09/16/2021
|
Co-Diagnostics says its CoSara JV received regulatory clearance in India for Saragene dengue and chikunguny tests
- Co-Diagnostics Inc has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene dengue and chikungunya RT-PCR tests as in vitro diagnostics (IVD). The Saragene test kits approved by the CDSCO use the company's patented CoPrimer technology for the qualitative detection of these mosquito-borne viruses.
- 09/16/2021
|
Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests
- SALT LAKE CITY, Sept. 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics ("IVD").
- 09/16/2021
|
Co-Diagnostics says its Logix Smart COVID-19 Test Kit used to confirm presence of coronavirus including mutated strains in Italy
- Co-Diagnostics Inc. reports that its Logix Smart COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus.
- 09/08/2021
|
Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy
- SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus, in a community surveillance method of testing single-use waste, with the peer-reviewed results published in the journal Science of the Total Environment.
- 09/08/2021
|
Why Co-Diagnostics Is A Solid Covid-19 Play
- Why Co-Diagnostics Is A Solid Covid-19 Play
- 08/19/2021
|
CoDiagnostics, Inc. (CODX) Just Reclaimed the 20-Day Moving Average
- Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
- 08/16/2021
|
Why Co-Diagnostics Zoomed Almost 10% Higher Today
- The company notched beats on both trailing and anticipated revenue and earnings.
- 08/13/2021
|
Co-Diagnostics Stock Moves Higher As Q2 Earnings Top Estimates
- Co-Diagnostics Inc's (NASDAQ: CODX) Q2 revenue increased 14% Y/Y to $27.4 million, primarily due to Logix Smart COVID-19 Test sales, beating the consensus of $20.77 million. Gross profit increased 37.6% to $24.9 million, with margin expanding to 90.8% from 75.1% in Q2 FY20 due to reduced production costs and improved product mix compared to the prior-year period.
- 08/13/2021
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q2 2021 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
CoDiagnostics, Inc. (CODX) Surpasses Q2 Earnings and Revenue Estimates
- CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 43.48% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Co-Diagnostics sees 2Q revenue rise by 13.8% driven by sales of the Logix Smart COVID-19 Test
- Co-Diagnostics (NASDAQ:CODX) Inc posted second-quarter results that saw pre-tax income of $11.9 million and year-over-year revenue gains driven by sales of the company's Logix Smart COVID-19 Test. For the period ended June 30, 2021, the Salt Lake City, Utah-based molecular diagnostics company reported revenue of $27.4 million, up 13.8% from the second quarter in 2020.
- 08/12/2021
|
Analysts Estimate CoDiagnostics, Inc. (CODX) to Report a Decline in Earnings: What to Look Out for
- CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/05/2021
|
Co-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast
- SALT LAKE CITY, Aug. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2021 results on Thursday, August 12, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 08/04/2021
|
Why Co-Diagnostics Blasted 21% Higher on Thursday
- The company was awarded a patent from a relatively affluent Asian country.
- 07/22/2021
|
Why Co-Diagnostics Shares Are Skyrocketing Today
- Co-Diagnostics Inc (NASDAQ:CODX) shares are trading higher by 26.3% at $10.99 Thursday afternoon. The stock spiked earlier following reports suggesting the Biden Administration will announce it is directing $1.6 billion for COVID testing in high-risk settings.
- 07/22/2021
|
Co-Diagnostics strengthens intellectual property portfolio with South Korean patent award for its CoPrimer technology
- Co-Diagnostics Inc has strengthened its intellectual property portfolio after being awarded a patent in the Republic of Korea for the company's CoPrimer technology. Developed in 2013, Co-Diagnostics' solely owned CoPrimer technology received its first patent from the United States Patent Office in 2018, and underpins the company's molecular diagnostic test products deployed in laboratories and hospitals in over 50 countries and across the US.
- 07/22/2021
|
Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent
- SALT LAKE CITY, July 22, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea's Intellectual Property Office for the Company's CoPrimer™ technology. Developed in 2013, Co-Diagnostics' solely-owned CoPrimer technology received its first patent from the United States Patent Office in 2018, and underpins the Company's molecular diagnostic test products that have been deployed in laboratories and hospitals in over 50 countries and across the United States.
- 07/22/2021
|
CODX Stock Increased 9.67%: Why It Happened
- The stock price of Co-Diagnostics Inc (NASDAQ: CODX) increased by 9.67% yesterday. This is why it happened.
- 07/20/2021
|
Strength Seen in CoDiagnostics, Inc. (CODX): Can Its 9.7% Jump Turn into More Strength?
- CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 07/20/2021
|
Why Coronavirus Stocks Are Zooming Higher Today
- The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.
- 07/19/2021
|
Are Investors Undervaluing CoDiagnostics, Inc. (CODX) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 07/01/2021
|
Co-Diagnostics says its Logix Smart coronavirus test has obtained regulatory authorization to be sold in markets that accept CE markings
- Co-Diagnostics, Inc. (NASDAQ:CODX) has announced that its Logix Smart SARS-CoV-2 DS (Direct Saliva) test has obtained regulatory authorization to be sold as an in vitro diagnostic (IVD) for the diagnosis of coronavirus (COVID-19) in markets that accept CE markings. The company noted that the test is available now for purchase from its Utah-based ISO-13485:2016 certified facility.
- 06/18/2021
|
Co-Diagnostics, Inc. says its Logix Smart coronavirus test has obtained regulatory authorization to be sold in markets that accept CE markings
- Co-Diagnostics, Inc. (NASDAQ:CODX) has announced that its Logix Smart SARS-CoV-2 DS (Direct Saliva) test has obtained regulatory authorization to be sold as an in vitro diagnostic (IVD) for the diagnosis of coronavirus (COVID-19) in markets that accept CE markings. The company noted that the test is available now for purchase from its Utah-based ISO-13485:2016 certified facility.
- 06/18/2021
|
Co-Diagnostics, Inc. says its Logix Smart cornavirus test has obtained regulatory authorization to be sold in markets that accept CE markings
- Co-Diagnostics, Inc. (NASDAQ:CODX) has announced that its Logix Smart SARS-CoV-2 DS (Direct Saliva) test has obtained regulatory authorization to be sold as an in vitro diagnostic (IVD) for the diagnosis of coronavirus (COVID-19) in markets that accept CE markings. The company noted that the test is available now for purchase from its Utah-based ISO-13485:2016 certified facility.
- 06/18/2021
|
Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test
- SALT LAKE CITY, June 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 DS (Direct Saliva) has obtained regulatory authorization to be sold as an in vitro diagnostic ("IVD") for the diagnosis of COVID-19 in markets that accept CE markings, and is now available for purchase from the Company's Utah-based ISO-13485:2016 certified facility. Co-Diagnostics' Logix Smart DS test kit is designed to detect the presence of the RdRp and E genes of SARS-CoV-2 directly from minimally processed human saliva samples while eliminating RNA extraction of the samples, a costly and time-consuming process required by most PCR tests.
- 06/18/2021
|
Wall Street takes a turn for the worse as investors eye Fed
- 12:15pm: The Dow was down 161 points, 0.5%, at 34,233 at midday. The Nasdaq lost 85 points, 0.6%, to 14,088, and the S&P 500 ticked down 11 points, 0.3%, to 4,244.
- 06/15/2021
|
Co-Diagnostics says it will be presenting virtually at two conferences this week
- Co-Diagnostics, Inc. (NASDAQ:CODX) said it will be presenting virtually this week at the 28th International Biodetection Technologies Conference, as well as hosting a virtual booth at the 65th Annual Caribbean Public Health Agency (CARPHA) Health Research Conference. The International Biodetection Technologies Conference is being held on June 18, 2021.
- 06/15/2021
|
Co-Diagnostics says it will be presenting virtually at two conferences virtually this week
- Co-Diagnostics, Inc. (NASDAQ:CODX) said it will be presenting virtually this week at the 28th International Biodetection Technologies Conference, as well as hosting a virtual booth at the 65th Annual Caribbean Public Health Agency (CARPHA) Health Research Conference. The International Biodetection Technologies Conference is being held on June 18, 2021.
- 06/15/2021
|
Co-Diagnostics: No One-Hit Wonder
- Vaccine hesitancy and new coronavirus variants are a threat to herd immunity. The alternative solution to vaccination for re-opening the economy is mass testing.
- 06/04/2021
|
5 Stocks To Watch For May 14, 2021
- Some of the stocks that may grab investor focus today are: Walt Disney Co (NYSE: DIS) reported upbeat earnings for its second quarter, while sales missed expectations. Disney+ ended the second quarter with 103.6 million subscribers.
- 05/14/2021
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q1 2021 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
CoDiagnostics, Inc. (CODX) Beats Q1 Earnings and Revenue Estimates
- CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 30.00% and 2.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
Recap: Co-Diagnostics Q1 Earnings
- Shares of Co-Diagnostics (NASDAQ:CODX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 620.00% year over year to $0.26, which beat the estimate of $0.22.
- 05/13/2021
|
Co-Diagnostics turns 1Q net profit of nearly $8M on strong sales of its Logix Smart COVID-19 Test
- Co-Diagnostics Inc (NASDAQ:CODX) reported that it earned a first-quarter net profit -- versus a loss last year -- on strong sales of its Logix Smart COVID-19 Test. For the quarter ended March 31, the company said income before taxes was $9.9 million as it generated revenue of $20 million.
- 05/13/2021
|
CoDiagnostics, Inc. (CODX) Earnings Expected to Grow: Should You Buy?
- CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2021
|
Co-Diagnostics, Inc. Announces First-Quarter 2021 Earnings Release Date and Webcast
- SALT LAKE CITY, May 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first-quarter 2021 results on Thursday, May 13, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 05/04/2021
|
Co-Diagnostics, Inc. and Partner CRL to Discuss Saliva Testing and Future Applications of PCR in 360Dx Webinar
- SALT LAKE CITY, April 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be accompanying Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Lab ("CRL") in a webinar titled "A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19" on Thursday, April 29 at 2:00 PM EDT. The 360Dx webinar is expected to provide insights regarding future applications of PCR testing for COVID-19, how CRL is able to provide non-invasive and highly accurate saliva PCR tests for at-home collection, and how new PCR science and technology is enabling and expanding the applications and accessibility of PCR tests.
- 04/29/2021
|
Co-Diagnostics says its CoSara joint venture in India garnering media attention as it combats coronavirus surge
- Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) diagnostics as a wave of infections has led to the world's worst outbreak since the pandemic began. An article in the Times of India, as well as other media sources, have discussed the increased capacity that has resulted from CoSara's efforts to provide test kits and technical support for its government and private lab customers, Co-Diagnostics said.
- 04/28/2021
|
Co-Diagnostics, Inc. JV CoSara Diagnostics Recognized for Work Combating COVID-19 Surge in India
- SALT LAKE CITY, April 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Indian manufacturing facility, CoSara Diagnostics Pvt. Ltd. ("CoSara," or the "JV", a Joint Venture with Synbiotics Ltd) has been featured in recent press highlighting its actions to provide much-needed COVID-19 diagnostics as a wave of infections has led to the world's worst COVID-19 outbreak since the pandemic began.
- 04/28/2021
|
5 Health Care Stocks Trading with Low Price-Earnings Ratios
- As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.
- 04/21/2021
|
Co-Diagnostics says Logix Smart COVID-19 Test performance validated by Australian researchers in peer-reviewed publication
- Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a patented platform for the development of diagnostic tests, has revealed that its Logix Smart COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the ‘Journal of Medical Microbiology.' The Utah-based company said the study was performed using readily available open-source equipment and materials that could be successfully operated in regional clinical laboratories, many of which are not currently equipped for molecular diagnostics.
- 04/20/2021
|
Co-Diagnostics, Inc. Test Performance Demonstrated by Australian Researchers in Peer-Reviewed Publication
- SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the Journal of Medical Microbiology. The test demonstrated an analytical sensitivity of 1010 viral copies/ml, comparable to others used across W.
- 04/20/2021
|
If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bail
- CODX stock rose on the pandemic, but its prospects moving forward look bleak with a sales strategy that is suspect at best. The post If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bail appeared first on InvestorPlace.
- 04/07/2021
|
Co-Diagnostics CEO Egan says individuals and organizations will need DIY coronavirus tests partnered with vaccines to return to normalcy
- Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy tests partnered with vaccines to return to normalcy.
- 03/31/2021
|
Co-Diagnostics CEO Eagan says individuals and organizations will need DIY coronavirus tests partnered with vaccines to return to normalcy
- Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy tests partnered with vaccines to return to normalcy.
- 03/31/2021
|
Co-Diagnostics, Inc. CEO Discusses Company Strategy for the Future with Yahoo! Finance
- SALT LAKE CITY, March 31, 2021 /PRNewswire/ -- The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, appeared yesterday on Yahoo! Finance to comment on the Company's recently-released FY2020 earnings report, and to discuss its going-forward strategy as the world struggles to achieve normalization.
- 03/31/2021
|
Co-Diagnostics CEO discusses coronavirus testing: We believe robust testing is key to normalizing
- coronavirustesting Yahoo Finance's Adam Shapiro and Seana Smith spoke with Co-Diagnostics CEO Dwight Egan about the company's outlook and the latest coronavirus testing methods.
- 03/30/2021
|
Co-Diagnostics: Buy the Dip?
- Analysts following this coronavirus stock have darkened their post-pandemic outlook.
- 03/29/2021
|
Why Co-Diagnostics Stock Is Dropping Today
- The company's recent struggles on the stock market continue.
- 03/29/2021
|
Co-Diagnostics, DocuSign, Dow, Nomura, Sea and More Monday Afternoon Analyst Calls
- With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of it with about 1% pullback.
- 03/29/2021
|
Co-Diagnostics joins fight against coronavirus (COVID-19) with flagship test
- Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnostics does: Co-Diagnostics Inc (NASDAQ:CODX) is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.
- 03/26/2021
|
Co-Diagnostics turns fight against infectious disease with flagship coronavirus (COVID-19) test
- Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnostics does: Co-Diagnostics Inc (NASDAQ:CODX) is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.
- 03/26/2021
|
Why Co-Diagnostics Stock Is Tanking Today
- Investors didn't like what they heard in the company's fourth-quarter update.
- 03/26/2021
|
What Investors Didn't Like About Co-Diagnostics' Q4 Update
- The company missed earnings expectations and hinted at slowing growth in 2021.
- 03/26/2021
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2020 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2020 Results - Earnings Call Transcript
- 03/25/2021
|
CoDiagnostics, Inc. (CODX) Q4 Earnings Lag Estimates
- CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -12.24% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/25/2021
|
Co-Diagnostics posts 2020 net income of $42.5M as its Logix Smart COVID-19 test drove record sales
- Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday that it earned a net income of $42.5 million in 2020 as its Logix Smart coronavirus (COVID-19) test drove record sales. That's a huge turnaround for the Utah-based molecular diagnostics company which posted a $5.6 million loss in 2019.
- 03/25/2021
|
Recap: Co-Diagnostics Q4 Earnings
- Shares of Co-Diagnostics (NASDAQ:CODX) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 577.78% year over year to $0.43, which missed the estimate of $0.48.
- 03/25/2021
|
Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results
- SALT LAKE CITY, March 25, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Financial Results: Revenue of $27.1 million, primarily due to sales of the Logix Smart™ COVID-19 Test Gross profit increased to $22.8 million, representing 84.1% of consolidated revenue due to improved product mix as compared to the prior-year period Operating income improved to $16.0 million, due to record revenue and gross profit Income before taxes of $15.8 million Net income of $12.8 million, compared to a net loss of $1.7 million in the prior-year fourth quarter, representing $0.43 per fully diluted share Full Year 2020 Financial Results: Revenue of $74.6 million, an increase of $74.3 million, primarily due to sales of Logix Smart COVID-19 Tests throughout the world Gross profit increased to $58.0 million, representing 77.7% of consolidated revenue Operating income improved to $41.7 million due to record revenue and gross profit for the year Income before taxes of $42.6 million Net income of $42.5 million, compared to a loss of $5.6 million from the prior year, representing $1.52 per fully diluted share, and reflecting a full utilization of historical net operating losses Cash, cash equivalents, and marketable securities totaled $47.3 million as of December 31, 2020, an increase of $46.4 million from December 31, 2019 "This year marked a critical inflection point in our ability to establish Co-Diagnostics as a leading global molecular diagnostic company, driving innovation through our proprietary technologies across the infectious disease market," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.
- 03/25/2021
|
Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings Release
- CODX stock's true value isn't fully appreciated by the investing community, and this could provide a setup for an explosive move. The post Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings Release appeared first on InvestorPlace.
- 03/25/2021
|
Co-Diagnostics, Inc. Announces Fourth-Quarter and Full-Year 2020 Earnings Release Date and Webcast
- SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth-quarter and full-year 2020 results on March 25, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
- 03/18/2021
|
Co-Diagnostics: A+ Student Faces New Tests
- Co-Diagnostics: A+ Student Faces New Tests
- 03/12/2021
|
Biotech Stocks: What Will 2021 Look Like?
- 2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?
- 03/12/2021
|
Co-Diagnostics is designing at-home coronavirus PCR saliva test delivering results by smartphone app
- Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. The small cube-shaped device is designed to perform COVID-19 testing at businesses, schools, homes, hotels, cruise ships, airports, airplanes and other locations.
- 03/02/2021
|
Co-Diagnostics designs at-home coronavirus PCR saliva test delivering results by smartphone app
- Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. The small cube-shaped device is designed to perform COVID-19 testing at businesses, schools, homes, hotels, cruise ships, airports, airplanes and other locations.
- 03/02/2021
|
Co-Diagnostics notes its CoPrimer technology powers coronavirus saliva test now available through Walgreens digital health platform
- Co-Diagnostics Inc (NASDAQ:CODX) has confirmed that its patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer's website and mobile app. In a statement on Thursday, Dwight Egan, Co-Diagnostics CEO commented: “Co-Diagnostics is proud that our technology will be available on an even more widespread basis following this announcement by our trusted partner CRL, one of the largest privately-held clinical testing laboratories in the U.S.
- 02/25/2021
|
Why Co-Diagnostics Stock Is Shooting Higher Today
- Its technology underpins a coronavirus test that's about to get much wider distribution.
- 02/24/2021
|
Co-Diagnostics' CoPrimer technology powers coronavirus saliva test now available through Walgreens digital health platform
- Co-Diagnostics Inc (NASDAQ:CODX) patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer's website and mobile app. The company's COVID-19 RT-PCR test is being sold by Clinical Reference Laboratory under its CRL HealthConfirm brand name for $119 per kit, according to a CRL statement released Wednesday.
- 02/24/2021
|
Co-Diagnostics Names New CFO and CSO
- With the latter appointment, the company's founder moves into a more advisory role.
- 02/23/2021
|
Co-Diagnostics appoints long-time executive Brian Brown as its new chief financial officer
- Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company's new chief financial officer (CFO). The company said Brown's previous experience includes CFO, vice president of accounting and investor relations, and director of finance roles for public and private companies.
- 02/23/2021
|
Co-Diagnostics, Inc. Announces New Chief Financial Officer
- SALT LAKE CITY, Feb. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is pleased to welcome Brian Brown, CPA to the position of Co-Diagnostics...
- 02/23/2021
|
Co-Diagnostics to present on direct saliva testing at Molecular Medicine Tri-Conference
- Co-Diagnostics Inc (NASDAQ:CODX) has said it will be presenting on direct saliva testing for coronavirus (COVID-19) at the 28th Annual International Molecular Medicine Tri-Conference, to be held virtually between February 16-18, 2021. Representatives of the molecular diagnostics specialist will introduce the Co-Diagnostics Logix Smart SARS-CoV-2 DS (Direct Saliva) kit, which the company has submitted for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA).
- 02/16/2021
|
CODX Stock Price Increased Over 80% This Past Month: Why It Happened
- The stock price of Co-Diagnostics Inc (NASDAQ: CODX) is up over 80% over the past month. This is why it happened.
- 02/09/2021
|
The Big Picture for Virus Testing Stocks (NASDAQ: FLGT) (OTC US: ALST) (NASDAQ: CODX)
- The good news is that the end of the pandemic is in sight. The bad news is that it may never really be over.
- 02/02/2021
|
Up 938% in 2020, Is Co-Diagnostics Still a Buy in 2021?
- This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.
- 01/30/2021
|
The 17 Stocks That Outperformed Tesla In 2020
- This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020.
- 01/21/2021
|
Forget Snowflake! Buy This Ultra-High-Growth Stock
- This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.
- 01/15/2021
|
Co-Diagnostics: Additional Factors For Consideration In The Investment Debate
- Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020. The company's Covid-19 tests are differentiated by distinguishing between common cold and SARS-CoV-2 with an easy to use platform.
- 01/12/2021
|
3 Top Coronavirus Stocks to Buy Right Now
- These companies are developing highly competitive vaccines and diagnostics.
- 01/06/2021
|
These Were the 3 Best Coronavirus Stocks of 2020
- Not all of them were COVID-19 vaccine makers.
- 01/01/2021
|
These Were the 5 Top Genetics Stocks of 2020
- Investors in fast-moving biotechs made out like bandits.
- 12/31/2020
|
A+ Top Quant Rated Healthcare Stocks For Value, Growth, And Profitability
- Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profitability tabs runs a significant gamut of the information properly considered in performing due diligence on a stock.
- 12/23/2020
|
These 5 Small-Cap Healthcare Stocks Gained the Most in 2020
- These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.
- 12/23/2020
|
These Were the 10 Best Healthcare Stocks of 2020
- The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?
- 12/15/2020
|
Co-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold
- SALT LAKE CITY, Dec. 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has sold over 10 million of its Logix Smart™...
- 12/14/2020
|
Up 1,000% in 2020, Is Co-Diagnostics Stock Still a Buy?
- The company has unbelievable top-line growth right now, and has profit margins over 60%. Will the stock continue to ride high once the world is vaccinated?
- 12/10/2020
|
Why Co-Diagnostics Stock Jumped Today
- The company's joint venture in India received good news.
- 11/25/2020
|
Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test
- SALT LAKE CITY, Nov. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"),...
- 11/25/2020
|
Why Co-Diagnostics Stock Is Getting Clobbered Today
- The company badly missed Wall Street earnings estimate for the third quarter.
- 11/17/2020
|
Co-Diagnostics, Inc. Receives CE Markings for "ABC" and SARS-CoV-2 2-Gene Multiplex Tests
- SALT LAKE CITY, Nov. 17, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC (Influenza A/B, SARS-CoV-2) and its Logix Smart™...
- 11/17/2020
|
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2020 Results - Earnings Call Transcript
- Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2020 Results - Earnings Call Transcript
- 11/16/2020
|
The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)
- The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)
- 11/11/2020
|
Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction
- SALT LAKE CITY, Nov. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company whitepaper demonstrates that the CoPrimer™ platform...
- 11/11/2020
|
Co-Diagnostics, Inc. Announces Q3 2020 Earnings Release Date and Earnings Webcast
- SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its third quarter 2020 earnings on November 16, 2020...
- 11/10/2020
|
Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share
- SALT LAKE CITY, Utah, Nov. 2, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following the discovery of an incorrectly recorded expense in...
- 11/02/2020
|
Co-Diagnostics, Inc. Logix Smart Kit to be Used with Newly Authorized Saline Oral Rinse Collection
- SALT LAKE CITY, Oct. 2, 2020 /PRNewswire via COMTEX/ --
SALT LAKE CITY, Oct. 2, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular...
- 10/02/2020
|
Pandemic Stocks Set to Thrive Again? (NASDAQ: CODX) (OTC PINK: ALST) (NASDAQ: SRNE)
- Oct 01, 2020 (OTC PR WIRE via COMTEX) --
We have started to see spikes in Covid-19 cases in Canada, the UK, Germany, Spain, and France over the past two...
- 10/01/2020
|
What We Learned About Co-Diagnostics' (NASDAQ:CODX) CEO Compensation
- Dwight Egan is the CEO of Co-Diagnostics, Inc. (NASDAQ:CODX), and in this article, we analyze the executive's...
- 08/18/2020
|
Co-Diagnostics Inc. (CODX) CEO Dwight H Egan on Q2 2020 Results - Earnings Call Transcript
- Co-Diagnostics Inc. (NASDAQ:CODX) Q2 2020 Earnings Conference Call August 13, 2020 04:30 PM ET Company Participants Andrew Benson - IR Dwight H Egan - CEO Reed Benson - CFO Conference Call Participants Yi Chen - HC Wainwright Michael Okunewitch - Maxim Group Theodore O'Neill - Litchfield Hills Research Presentation Operator Good afternoon, everyone, and welcome to the Co-Diagnostics Q2 2020 Earnings Conference Call.
- 08/17/2020
|
Co-Diagnostics CEO on COVID-19 testing delays: We're 'not part of that log jam'
- Co-Diagnostics CEO Dwight Egan, joins Yahoo Finance's Zack Guzman to discuss the company's second-quarter earnings results, as it plans to deploy new flu and coronavirus test panels.
- 08/17/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of USO, CODX and GEO
- NEW YORK, NY / ACCESSWIRE / August 17, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies.
- 08/17/2020
|
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ...
- 08/17/2020
|
CODX FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Co-Diagnostics, Inc. Investors of the Important August 17 Deadline in Securities Class Action - CODX
- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the "Class Period"), of the important August 17, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Co-Diagnostics investors under the federal securities laws.
- 08/17/2020
|
CODX LOOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020
- New York, New York--(Newsfile Corp. - August 17, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 and May 15, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting ...
- 08/17/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CODX
- New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Co-Diagnostics, Inc. ("Co-Diagnostics") (NASDAQ: CODX) between February 25, 2020 and May 15, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the District of Utah. To get more information ...
- 08/17/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ENDP, CSPR and CODX
- NEW YORK, NY / ACCESSWIRE / August 17, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.
- 08/17/2020
|
CODX DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020
- NEW YORK, NY / ACCESSWIRE / August 16, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc.
- 08/16/2020
|
DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ: CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, ...
- 08/16/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CSPR, CODX and WINS
- NEW YORK, NY / ACCESSWIRE / August 16, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.
- 08/16/2020
|
FINAL DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / August 15, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc.
- 08/15/2020
|
SHAREHOLDER ALERT: CEMI CODX KL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / August 14, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies.
- 08/14/2020
|
3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / August 14, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc.
- 08/14/2020
|
CODX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2020 in the Class Action Filed on Behalf of Co-Diagnostics, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - August 14, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Co-Diagnostics, Inc. (NASDAQ: CODX) alleging that the Company violated federal securities laws.Class Period: February 25, 2020 and May 15, 2020Lead Plaintiff Deadline: August 17, 2020Learn more about your recoverable losses in DNK:http://www.kleinstocklaw.com/pslra-1/co-diagnostics-inc-loss-submission-form?id=8585&from=5According to the filed complaint, Co-Diagnostics and its directors and officers (including PhD-level scientists ...
- 08/14/2020
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX)
- The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) securities between February 25, 2020 and May 15, 2020, inclusive (the "Class Period").
- 08/14/2020
|
CODX DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020
- NEW YORK, NY / ACCESSWIRE / August 14, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc.
- 08/14/2020
|
Why Co-Diagnostics Stock Is Tanking Today
- What happened Shares of Co-Diagnostics (NASDAQ: CODX) were 22.8% lower as of 10:55 a.m. EDT on Friday. The big drop came after the molecular diagnostics company announced its second-quarter results following the market close on Thursday.
- 08/14/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ENPH, CODX and KL
- NEW YORK, NY / ACCESSWIRE / August 14, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.
- 08/14/2020
|
MONDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 14, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, ...
- 08/14/2020
|
Co-Diagnostics Plummets 16% After Hours on Q2 Misses
- Co-Diagnostics (NASDAQ: CODX), a medical testing company that has risen sharply in both prominence and share price since the beginning of this year, fell hard in after-hours trading on Thursday. For the quarter, the details of which were released after market close, Co-Diagnostics earned just over $24 million in net revenue thanks to sales of its Logix Smart COVID-19 testing kit.
- 08/14/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CODX
- New York, New York--(Newsfile Corp. - August 13, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Co-Diagnostics, Inc. ("Co-Diagnostics") (NASDAQ: CODX) between February 25, 2020 and May 15, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the District of Utah. To get more information ...
- 08/14/2020
|
4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / August 13, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc.
- 08/13/2020
|
Co-Diagnostics, Inc. Announces Q2 2020 Results on Form 10-Q
- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the filing of its operating results for the 3 month period ending June 30, 2020 on SEC Form 10-Q, and provided updates on Company developments.
- 08/13/2020
|
LAWSUITS FILED AGAINST CODX, ERII and GWRE - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / August 13, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below.
- 08/13/2020
|
CODX FINAL DEADLINE: ROSEN, A LEADING FIRM, Encourages Co-Diagnostics, Inc. Investors to Contact Firm Before Important August 17 Deadline in Securities Class Action Seeking Recovery of Investor Losses - CODX
- NEW YORK, NY / ACCESSWIRE / August 13, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc.
- 08/13/2020
|
CLASS ACTION UPDATE for ENDP, CODX and BAYRY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / August 13, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.
- 08/13/2020
|
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 13, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ...
- 08/13/2020
|
Dow Jones Today, Futures Backtrack As Cisco Systems Dives
- Tesla led the Nasdaq, Cisco Systems dragged on the S&P 500 and the Dow Jones today, as stock futures pulled back after Wednesday's rally.
- 08/13/2020
|
Lawsuits Filed Against CEMI, CSPR and CODX - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / August 12, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below.
- 08/12/2020
|
5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / August 12, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc.
- 08/12/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRA, CEMI and CODX
- NEW YORK, NY / ACCESSWIRE / August 12, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies.
- 08/12/2020
|
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Co-Diagnostics, Inc. (NASDAQ: CODX) securities between February 25, 2020 and May 15, 2020 (the "Class Period"). Investors have until August 17, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 08/12/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Co-Diagnostics, Inc. of Class Action Lawsuit and Upcoming Deadline - CODX
- NEW YORK, NY / ACCESSWIRE / August 12, 2020 / Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc.
- 08/12/2020
|
SHAREHOLDER ALERT: ENDP CODX ERII: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / August 12, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies.
- 08/12/2020
|
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 12, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ: CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, ...
- 08/12/2020
|
CODX LOOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020
- NEW YORK, NY / ACCESSWIRE / August 11, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc.
- 08/11/2020
|
Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store?
- Co-Diagnostics' (CODX) second-quarter results are likely to reflect higher COVID-19 test sales.
- 08/11/2020
|
Co-Diagnostics, Inc. Announces Q2 2020 Earnings Release Date and Earnings Webcast
- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its second quarter 2020 earnings on August 13, 2020 after the close of trading on that day, and will hold an earnings call at 4:30 pm EDT. The call is expected to consist of prepared remarks by Company CEO Dwight Egan.
- 08/11/2020
|
LAWSUITS FILED AGAINST CODX, FE and UCO - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below.
- 08/10/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CEMI, CODX and VEL
- NEW YORK, NY / ACCESSWIRE / August 10, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies.
- 08/10/2020
|
CODX UPCOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020
- NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc.
- 08/10/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of USO, CODX and VEL
- NEW YORK, NY / ACCESSWIRE / August 10, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies.
- 08/10/2020
|
CLASS ACTION UPDATE for CEMI, CODX and BKD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.
- 08/10/2020
|
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Reminds Co-Diagnostics, Inc. Investors of Important August 17 Deadline in Securities Class Action - CODX
- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the "Class Period"), of the important August 17, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Co-Diagnostics investors under the federal securities laws.
- 08/08/2020
|
CLASS ACTION UPDATE for CEMI, CODX and IDEX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / August 7, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.
- 08/07/2020
|
COVID-19 Impacts: Coronavirus Test Kits Market in Europe will Decelerate at a CAGR of over -32% through 2020-2024 | Increasing Government Funding to Boost Growth | Technavio
- The Coronavirus Test Kits Market in Europe will grow by USD -139.05 mn during 2020-2024
- 08/07/2020
|
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Co-Diagnostics, ProAssurance, Enphase, and Chembio and Encourages Investors to Contact the Firm
- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of
- 08/05/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
Why Shares Of Co-Diagnostics Are Soaring
- Co-Diagnostics Inc (NASDAQ: CODX) shares were headed higher Monday after the company said the FDA has authorized the use of its technology in a third-party, self-administered...
- 08/03/2020
|
Biotech Bonanza - Second Half Outlook
- Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
- 07/28/2020
|
Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day
- Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day
- 07/17/2020
|
SHAREHOLDER ALERT: PRA WFC CODX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / July 17, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, ...
- 07/17/2020
|
Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - July 17, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ:CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 and ...
- 07/17/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PRA, ENPH and CODX
- NEW YORK, NY / ACCESSWIRE / July 16, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 07/16/2020
|
DEADLINE ALERT for PRA, CODX, ENPH, and CEMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
- LOS ANGELES, July 16, 2020 -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following.
- 07/16/2020
|
DEADLINE ALERT for HEBT, KNDI, PRA, CODX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
- BENSALEM, Pa., July 16, 2020 -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following.
- 07/16/2020
|
CLASS ACTION UPDATE for PRA, CLNY and CODX: Levi and Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / July 16, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- 07/16/2020
|
Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - July 15, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 ...
- 07/16/2020
|
Co-Diagnostics: Soaring Demand for COVID-19 Test Kits Could Propel the Stock Even Higher
- A stock with a 6-month gain of over 1500% is normally certain to raise some eyebrows. But, “normally” is a long distance away from the current reality, and that figure is the upside posted by shares of molecular diagnostics player Co-Diagnostics (CODX) since the turn of the year.While certainly not common place, these massive gains are not completely out of the ordinary in 2020, although primarily reserved for one specific group of stocks: those in the hunt for coronavirus related solutions.And CODX belongs squarely in that group. Actually, that’s not quite on point - Co-Diagnostics already has a solution, in the shape of its Logix Smart COVID-19 test.The U.S. has seen an explosion of new infections in several states, as the rush to re-open the economy has backfired. The record number of COVID-19 cases reported over the last few days signal that there is no end in sight to the pandemic just yet.H.C. Wainwright analyst Yi Chen believes this will result in a growing need for Co-diagnostics’ test kit.The 5-star analyst noted, “What is clear now is that testing demand has been steadily increasing and is likely to continue to remain at a substantial level in the coming quarters, in our view. In fact, as reported in the Wall Street Journal yesterday, the COVID-19 testing system is reaching the brink in the U.S. as growing demand surpasses what the nation’s labs can handle, resulting in supply shortages and backlogs.”“Therefore,” Chen concludes, “we believe Co-Diagnostics should continue to ship a high volume of its Logix Smart™ COVID-19 test kits, with an increasing volume shipped to U.S. customers.”Accordingly, Chen rates CODX shares a Buy along with a $35 price target. There is potential for nearly 100% upside, should the figure be met in the year ahead. (To watch Chen’s track record, click here)In the last 3 months, two of Chen’s colleagues have also chipped in with a view on the diagnostics specialist’s prospects, both recommending a Buy. CODX 's Strong Buy consensus rating is backed by a $33.67 average price target and implies shares will appreciate by a hefty 93% in the next 12 months. (See Co-Diagnostics stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/16/2020
|
LAWSUITS FILED AGAINST CODX, GEO and WRCDF - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / July 15, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who ...
- 07/16/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Co-Diagnostics, Inc.  of Class Action Lawsuit and Upcoming Deadline – CODX
- NEW YORK, July 15, 2020 -- Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”)(NASDAQ: CODX) and.
- 07/15/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRA, CODX and JCOM
- NEW YORK, NY / ACCESSWIRE / July 15, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders ...
- 07/15/2020
|
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hebron Technology, Co-Diagnostics, ProAssurance, and Enphase Energy and Encourages Investors to Contact the Firm
- NEW YORK, July 15, 2020 -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on.
- 07/15/2020
|
LAWSUITS FILED AGAINST PRA, CEMI and CODX - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / July 15, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who ...
- 07/15/2020
|
CODX INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- New York, New York--(Newsfile Corp. - July 15, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 and May 15, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by ...
- 07/15/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CODX
- New York, New York--(Newsfile Corp. - July 13, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Co-Diagnostics, Inc. ("Co-Diagnostics") (NASDAQ: CODX) between February 25, 2020 and May 15, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the District of Utah. To get more ...
- 07/14/2020
|
Analysis on New Product Launches in COVID-19 Related Markets: Coronavirus Test Kits Market in APAC- Vendor Analysis and Growth Outlook for 2020-2024: Exclusive Report from Technavio
- The Coronavirus Test Kits Market in APAC will grow by USD 50.15 mn during 2020-2024
- 07/14/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Co-Diagnostics, Inc. of Class Action Lawsuit and Upcoming Deadline - CODX
- NEW YORK, NY / ACCESSWIRE / July 13, 2020 / Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company")(CODX) and certain of its officers. The class action, filed in United States District Court for the District of Utah, Central Division, and indexed under 20-cv-00481, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020, and May 15, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/13/2020
|
LAWSUITS FILED AGAINST LOPE, CODX and KL - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / July 13, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who ...
- 07/13/2020
|
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX)
- LOS ANGELES, July 13, 2020 -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class.
- 07/13/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRNE, CODX and GEO
- NEW YORK, NY / ACCESSWIRE / July 13, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 07/13/2020
|
LOSS NOTICE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Co-Diagnostics, Inc. Investors of Important August 17 Deadline in Securities Class Action - CODX
- NEW YORK, NY / ACCESSWIRE / July 12, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ:CODX) between February 25, 2020 and May ...
- 07/12/2020
|
CLASS ACTION UPDATE for PRA, WFC and CODX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / July 10, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- 07/10/2020
|
Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - July 10, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 and ...
- 07/10/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ENDP, CODX and GEO
- NEW YORK, NY / ACCESSWIRE / July 10, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 07/10/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / July 9, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period'') are encouraged to contact the firm before August 17, 2020.
- 07/10/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CLNY, CODX and IDEX
- NEW YORK, NY / ACCESSWIRE / July 9, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders ...
- 07/09/2020
|
Shareholder Alert: Robbins LLP Reminds Investors Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders
- Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 25, 2020 and May 15, 2020. Co-Diagnostics is a molecular diagnostics company that intends to manufacture and sell reagents used for diagnostic tests.
- 07/09/2020
|
CLASS ACTION UPDATE for PRA, CODX and BKD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / July 9, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 07/09/2020
|
DEADLINE ALERT for HEBT, KNDI, PRA, CODX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
- BENSALEM, Pa., July 09, 2020 -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following.
- 07/09/2020
|
CODX SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, July 09, 2020 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics,.
- 07/09/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CEMI, CODX and IDEX
- NEW YORK, NY / ACCESSWIRE / July 9, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders ...
- 07/09/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CODX
- New York, New York--(Newsfile Corp. - July 7, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Co-Diagnostics, Inc. ("Co-Diagnostics") (NASDAQ: CODX) between February 25, 2020 and May 15, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the District of Utah. To get more information ...
- 07/08/2020
|
SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / July 7, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period'') are encouraged to contact the firm before August 17, 2020.
- 07/07/2020
|
LAWSUITS FILED AGAINST WFC, CEMI and CODX - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / July 7, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 07/07/2020
|
Co-Diagnostics Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - July 7, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 ...
- 07/07/2020
|
SHAREHOLDER ALERT: ENDP CODX BKD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / July 6, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...
- 07/07/2020
|
SHAREHOLDER ALERT: ENDP CODX IDEX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / July 6, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...
- 07/07/2020
|
CLASS ACTION UPDATE for ENDP, CODX and IDEX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / July 6, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 07/07/2020
|
Pomerantz Law Firm Announces the Filing of a Class Action against Co-Diagnostics, Inc. and Certain Officers – CODX
- Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”)(CODX) and certain of its officers. The class action, filed in United States District Court for the District of Utah, Central Division, and indexed under 20-cv-00481, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020, and May 15, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/06/2020
|
Co-Diagnostics: COVID-19 Test Sales Push Up Its Price (NASDAQ:CODX)
- Co-Diagnostics develops tools for detecting infectious diseases, cancer, and agricultural software. It reported stock gains of more than 2,190%. In a recent pre
- 07/06/2020
|
Notice of Lead Plaintiff Deadline for Shareholders in the Co-Diagnostics, Inc. Class Action Lawsuit
- Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Utah on behalf of purchasers of Co-Diagno
- 07/06/2020
|
Engineers Gate Manager LP Buys New Shares in Co-Diagnostics Inc (NASDAQ:CODX)
- Engineers Gate Manager LP bought a new stake in Co-Diagnostics Inc (NASDAQ:CODX) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 27,998 shares of the company’s stock, valued at approximately $213,000. Other institutional investors also recently added to or reduced their stakes in the […]
- 07/04/2020
|
CLASS ACTION UPDATE for PRA, CEMI and CODX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / July 2, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 07/02/2020
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / July 2, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period'') are encouraged to contact the firm before August 17, 2020.
- 07/02/2020
|
LAWSUITS FILED AGAINST PRA, CODX and IDEX - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / July 2, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 07/02/2020
|
Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - July 2, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 ...
- 07/02/2020
|
DEADLINE ALERT for KNDI, PRA, CODX, ENPH: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
- BENSALEM, Pa., July 02, 2020 -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following.
- 07/02/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CODX
- New York, New York--(Newsfile Corp. - July 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Co-Diagnostics, Inc. ("Co-Diagnostics") (NASDAQ: CODX) between February 25, 2020 and May 15, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the District of Utah. To get more information ...
- 07/02/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Co-Diagnostics, Inc. - CODX
- NEW YORK, NY / ACCESSWIRE / July 1, 2020 / Pomerantz LLP is investigating claims on behalf of investors Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (CODX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Co-Diagnostics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 07/02/2020
|
SHAREHOLDER ALERT: HALL CEMI CODX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / July 1, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...
- 07/01/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / July 1, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period'') are encouraged to contact the firm before August 17, 2020.
- 07/01/2020
|
ROSEN, A HIGHLY RECOGNIZED INVESTOR FIRM, Reminds Co-Diagnostics, Inc. Investors of Important August 17 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CODX
- NEW YORK, July 01, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25,.
- 07/01/2020
|
CLASS ACTION UPDATE for WFC, FSCT and CODX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / July 1, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 07/01/2020
|
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fargo, Hebron Technology, Co-Diagnostics, and ProAssurance and Encourages Investors to Contact the Firm
- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Wells Fargo & Company (WFC), Hebron Technology Co., Ltd. (HEBT), Co-Diagnostics, Inc. (CODX), and ProAssurance Corporation (PRA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
- 07/01/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRA, ENPH and CODX
- NEW YORK, NY / ACCESSWIRE / July 1, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...
- 07/01/2020
|
DEADLINE ALERT for PRA, CODX, ENPH, and CEMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.
- 07/01/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CODX, BKD and KL
- NEW YORK, NY / ACCESSWIRE / July 1, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...
- 07/01/2020
|
CODX SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, NY / ACCESSWIRE / July 1, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the ...
- 07/01/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LOPE, CONN and CODX
- NEW YORK, NY / ACCESSWIRE / June 30, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 07/01/2020
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 30, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period'') are encouraged to contact the firm before August 17, 2020.
- 07/01/2020
|
6 Stocks That Could Shoot Higher
- Stocks Analysis by Harry Boxer covering: Crocs Inc, Tesla Inc, Celldex Therapeutics Inc, GenMark Diagnostics Inc. Read Harry Boxer's latest article on Investing.com
- 07/01/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CEMI, CODX and IDEX
- NEW YORK, NY / ACCESSWIRE / June 30, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 06/30/2020
|
Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - June 30, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ:CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 and would ...
- 06/30/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CODX
- New York, New York--(Newsfile Corp. - June 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Co-Diagnostics, Inc. ("Co-Diagnostics") (NASDAQ: CODX) between February 25, 2020 and May 15, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the District of Utah. To get more information ...
- 06/30/2020
|
CODX INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17
- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of those who acquired Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) securities during the period from February 25, 2020 through May 15, 2020. Investors have until August 17, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 06/29/2020
|
3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential
- COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the possible reversal of reopening measures spooked the market, with the three major U.S. stock indexes landing in the red on June 26.The resiliency of the virus has understandably alarmed investors, as the pandemic has devasted certain areas of the market. That being said, others have boomed during these tumultuous times. Looking specifically at the biotech sector, massive amounts of capital have been pumped into a handful of names racing to develop solutions to combat the virus. In the last three months, the NASDAQ Biotechnology Index (NBI) has climbed 29% higher, leaving the S&P; 500’s 18% gain in the dust.As some Wall Street analysts believe that a few of these coronavirus stocks still have plenty of room to grow, we took advantage of TipRanks’ database to get the lowdown on three of them. The platform revealed that each has earned a “Strong Buy” consensus rating from the analyst community and boasts substantial upside potential.Co-Diagnostics Inc. (CODX)Hoping to bring high-quality molecular diagnostics for infectious diseases to market, Co-Diagnostics uses unique technology that allows for more affordable testing, research and design solutions. Based on the potential of its Logix Smart COVID-19 test, this name has landed under Wall Street’s microscope.Writing for H.C. Wainwright, 5-star analyst Yi Chen tells clients that he has been impressed by the company, to say the least. On May 26, CODX announced that its product had been able to detect SARS-CoV-2 in formalin-fixed paraffin-embedded (FFPE) samples from surgical resection of tongue squamous cell carcinoma in a patient who developed COVID-19 after surgery. The analyst noted, “RNA of SARS-CoV-2 strain was detected in the tumor and the normal submandibular gland samples using the Logix Smart COVID-19 real-time PCR test, but no viral RNA was found in metastatic and reactive lymph nodes.”What is the implication of these results? Chen stated, “The results demonstrated that SARS-CoV-2 RNA can be detected in routine histopathological samples even before COVID-19 disease development...The published results bode well for the test’s market prospects in the coming months, in our view, as employers around the world are planning to test asymptomatic employees to allow them to return to the workplace.”The test’s impressive capabilities speak to the strength of CODX’s CoPrimer technology, “which effectively eliminates the propagation of primer-dimers normally found in PCR and increases the test's sensitivity and specificity”, in Chen’s opinion.On top of this, the biotech is developing additional tests to address the other obstacles in the diagnosis of a COVID-19 infection. These include a multiplex panel to distinguish between the COVID-19 virus and other upper respiratory pathogens, a test for the D614G mutation in SARS-CoV-2, which has been the most common strain in the U.S. as well as a test using CoPrimers to identify both the virus and the antibody associated with a past infection in one test.“In our view, these new tests could differentiate the company’s offerings from other PCR tests and further drive market adoption of CoPrimer-based COVID-19 testing,” Chen commented.With CODX also boasting more than $100 million worth of tests as of mid-May that should be shipped to customers in the coming months, the deal is sealed for Chen. In addition to reiterating a Buy recommendation, he kept a $35 price target on the stock, implying 103% upside potential. (To watch Chen’s track record, click here) Do other analysts agree with Chen? They do. Only Buy ratings, 3, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $33.67, the average price target brings the potential twelve-month gain to 95%. (See CODX stock analysis on TipRanks)Kiniksa Pharmaceuticals (KNSA)Primarily focused on developing therapeutic medicines designed to modulate immunological signaling pathways, Kiniksa wants to address the unmet medical needs of patients. Its potential COVID-19 treatment, mavrilimumab (mavri), has already produced promising results, with several members of the Street now singing its praises.Based on new data released from an open-label, single-active arm, single center study in Italy in non-mechanically ventilated patients with severe COVID-19 pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement.Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir/ritonavir as well as respiratory support with supplemental oxygen and/or non-invasive ventilation with continuous positive airway pressure open admission. It should also be noted that the study featured 13 patients treated with a single IV dose of mavrilimumab, compared to 26 contemporaneous patients that received local standard of care.“Twice as many patients on mavri showed clinical improvement vs. control subjects and that clinical improvement happened earlier on mavri (median 8 days vs. not estimable). There were no deaths on mavri vs. 27% for control and only 8% of mavri patients required ventilation vs. 5% for the control group. Mavri patients also were discharged earlier as well,” Bayko commented.As for what it all means, the five-star analyst said, “The data looks positive to us with standard caveats of small numbers and design limitations... The data continues to support our belief that mavrilimumab’s mechanism of action is well suited to treat COVID-19 patients.”Going forward, KNSA is discussing a registrational program for mavri with the FDA, and investigator-initiated, placebo-controlled studies are being planned in both the U.S. and Italy.Everything that KNSA has going for it prompted Bayko to stay with the bulls. Along with a Market Outperform rating, she maintained her $40 price target. This target implies shares could climb 55% higher in the next year. (To watch Bayko’s track record, click here) Like Bayko, other analysts also take a bullish approach. KNSA’s Strong Buy consensus rating breaks down into 5 Buys and zero Holds or Sells. Given the $31 average price target, the upside potential lands at 32%. (See Kiniksa stock analysis on TipRanks)Moderna, Inc. (MRNA)Last but not least, we come across Moderna, which has grabbed headlines left and right as a result of its experimental COVID-19 vaccine, mRNA-1273.Representing Piper Sandler, 5-star analyst Edward Tenthoff has high hopes based on early data. After MRNA published a preprint of mRNA-1273 preclinical data while simultaneously under peer-review for publishing in a leading medical journal, the analyst tells investors that the data suggests “mRNA-1273 supports clinical activity in humans.”“mRNA-1273 formulated in lipid nanoparticles elicited a balance both humoral (antibody) and cellular (CD8 T cell) immunity. Mice immunized with 0.0025-20mcg of mRNA-1273 demonstrated strong dose-dependent correlation between binding and neutralizing antibody responses. Importantly, mice receiving two 1.0mcg doses of mRNA-1273 were completely protected from viral replication in lungs and nasal cavities after re-challenge at 5- and 13-weeks following boost,” Tenthoff explained.Looking more closely at the candidate, it targets a pre-fusion Spike protein stabilized by two proline substitutions. This is important as it could allow for a more generalizable approach to be used to protect against mutations.It should also be noted that the Phase 2 study of mRNA-1273 has already enrolled 300 healthy adults aged 18-55 years, and 50 out of 300 subjects over the age of 55. According to Tenthoff, the data from this study should “further validate safety and efficacy of the 100µg dose in a broader population, which was selected for the Phase 3 trial.” This trial is set to kick off in July.Tenthoff added, “Lonza will support manufacturing of 500 million-1 billion doses per year. mRNA-1273 holds Fast Track Designation.”Based on all of the above, it’s no wonder Tenthoff reiterated his Overweight rating. With a $100 price target, shares could gain 61% in the next twelve months. (To watch Tenthoff’s track record, click here) Looking at the consensus breakdown, other analysts are on the same page. With 11 Buys and 2 Holds, the word on the Street is that MRNA is a Strong Buy. The $87.64 average price target puts the upside potential at 42%. (See Moderna stock-price forecast on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/29/2020
|
SHAREHOLDER ALERT: LOPE SRNE CODX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / June 29, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, ...
- 06/29/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Co-Diagnostics, Inc. - CODX
- Pomerantz LLP is investigating claims on behalf of investors Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (CODX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Co-Diagnostics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 06/29/2020
|
CODX INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17
- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Utah o
- 06/29/2020
|
CODX LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Co-Diagnostics, Inc. Investors of Important Deadline in Securities Class Action – CODX | MarketScreener
|
CODX LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Co-Diagnostics, Inc. Investors of Important Deadline in Securities Class Action – CODX
- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the "Class Period") of the important August 17, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Co-Diagnostics investors under the federal securities laws.
- 06/27/2020
|
Co-Diagnostics Class Action Reminder: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - June 27, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 and ...
- 06/27/2020
|
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
- Johnson Fistel, LLP, announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff, you must move the Court no later than the dates listed below. If you want to discuss this action or have any questions concerning this notice, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.
- 06/27/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period'') are encouraged to contact the firm before August 17, 2020.
- 06/26/2020
|
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX) | MarketScreener
|
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX)
- Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc.
- 06/26/2020
|
CODX SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 and May 15, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/codx.
- 06/26/2020
|
Co-Diagnostics Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - June 25, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company") of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Co-Diagnostics stock or options between February 25, 2020 and ...
- 06/26/2020
|
CODX SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. (
- 06/26/2020
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 25, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 17, 2020.
- 06/25/2020
|
Implied Volatility Surging for Co-Diagnostics (CODX) Stock Options
- Investors need to pay close attention to Co-Diagnostics (CODX) stock based on the movements in the options market lately.
- 06/25/2020
|
ROSEN, A GLOBALLY RECOGNIZED FIRM, Announces Filing of Securities Class Action Lawsuit Against Co-Diagnostics, Inc. – CODX
|
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Co-Diagnostics, Inc. - CODX
|
CODX INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, NY / ACCESSWIRE / June 24, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or ...
- 06/24/2020
|
Diagnostics : Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX) | MarketScreener
|
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX)
- Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX)
- 06/24/2020
|
NASDAQ: CODX Investor Notice: Lawsuit against Co-Diagnostics, Inc. announced by Shareholders Foundation
- SAN DIEGO, CA / ACCESSWIRE / June 24, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Co-Diagnostics, Inc. (NASDAQ:CODX) shares. Investors, who purchased ...
- 06/24/2020
|
6 Stocks With More Room To Run
- Stocks Analysis by Harry Boxer covering: Ballard Power Systems Inc, First Solar Inc, Dynavax Technologies Corporation, Limelight Networks Inc. Read Harry Boxer's latest article on Investing.com
- 06/24/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 23, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 17, 2020.
- 06/23/2020
|
Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - June 23, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company") of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Co-Diagnostics stock or options between February 25, 2020 and May ...
- 06/23/2020
|
CODX Kirby McInerney LLP Announces That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17 | MarketScreener
|
CODX INVESTOR ALERT: Kirby McInerney LLP Announces That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17
- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of those who acquired Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) securities during the period from February 25, 2020 through May 15, 2020. Investors have until August 17, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 06/22/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Co-Diagnostics, Inc. - CODX
- Pomerantz LLP is investigating claims on behalf of investors Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (CODX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Co-Diagnostics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 06/22/2020
|
ROSEN, A LEADING NATIONAL FIRM, Announces Filing of Securities Class Action Lawsuit Against Co-Diagnostics, Inc. - CODX
- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Co-Diagnostics investors under the federal securities laws.
- 06/22/2020
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 17, 2020.
- 06/22/2020
|
CODX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or ...
- 06/22/2020
|
Co-Diagnostics Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - June 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company") of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Co-Diagnostics stock or options between February 25, 2020 and May ...
- 06/22/2020
|
Co-Diagnostics Stock: Trading the Russell 2000 Index Catalyst
- Co-Diagnostics will be on the move over the next week. Don't confuse a technical trade for a strong long-term investment case in CODX stock.
- 06/22/2020
|
CODX INVESTOR ALERT: Kirby McInerney LLP Announces That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17
- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Utah on behalf
- 06/22/2020
|
Week 26 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
- Two sample Breakout Stocks for Week 26 with better than 10% short-term upside potential and a Dow 30 breakout selection. Last week three stocks peaked over 9.7%
- 06/21/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Co-Diagnostics, Inc. - CODX
- NEW YORK, NY / ACCESSWIRE / June 20, 2020 / Pomerantz LLP is investigating claims on behalf of investors Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (CODX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Co-Diagnostics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 06/20/2020
|
CO-DIAGNOSTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
|
CO-DIAGNOSTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
- 06/20/2020
|
CO-DIAGNOSTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- NEW YORK, June 20, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc....
- 06/20/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 19, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2020 and May 15, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 17, 2020.
- 06/19/2020
|
Glancy Prongay & Murray LLP : Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors | MarketScreener
|
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors
- Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors
- 06/19/2020
|
The Law Offices of Frank R. Cruz : Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. Investors (CODX) | MarketScreener
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. Investors (CODX)
- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) securities between February 25, 2020 and May 15, 2020, inclusive (the "Class Period"). Co-Diagnostics investors have until August 17, 2020 to file a lead plaintiff motion.
- 06/19/2020
|
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors | MarketScreener
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors
- 06/19/2020
|
CODX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 and May 15, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/codx.
- 06/19/2020
|
Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - June 19, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company") of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Co-Diagnostics stock or options between February 25, 2020 and May ...
- 06/19/2020
|
Coronavirus Test Kits Market in APAC 2020-2024 | Increasing Incidence Of Coronavirus to Boost Growth | Technavio
- The Coronavirus Test Kits Market in APAC will grow by $ 50.15 million during 2020-2024
- 06/19/2020
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Enphase Energy, Inc. Investors (ENPH)
- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Enphase Energy, Inc. ("Enphase" or the "Company") (NASDAQ: ENPH) securities between February 26, 2019 and June 17, 2020, inclusive (the "Class Period"). Enphase investors have until August 17, 2020 to file a lead plaintiff motion.
- 06/18/2020
|
CO-DIAGNOSTICS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm | MarketScreener
|
CO-DIAGNOSTICS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Co-Diagnostics, Inc. (NASDAQ: CODX) securities between February 25, 2020 and May 15, 2020 (the "Class Period"). Investors have until August 17, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 06/18/2020
|
Shareholder Alert: Robbins LLP Announces Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders | MarketScreener
|
Shareholder Alert: Robbins LLP Announces Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders
- Shareholder rights law firm Robbins LLP announces that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 25, 2020 and May 15, 2020. Co-Diagnostics is a molecular diagnostics company that intends to manufacture and sell reagents used for diagnostic tests.
- 06/18/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Co-Diagnostics, Inc. - CODX
- Pomerantz LLP is investigating claims on behalf of investors Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (CODX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Co-Diagnostics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 06/18/2020
|
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of Co-Diagnostics, Inc. (CODX) on Behalf of Investors | | IT Business Net
- LOS ANGELES--(BUSINESS WIRE)--$CODX #fraud--Glancy Prongay & Murray LLP ("GPM"), a national investor rights law firm, today announced that it has commenced an investigation on behalf of
- 06/18/2020
|
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of Co-Diagnostics, Inc. (CODX) on Behalf of Investors
- Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of Co-Diagnostics, Inc. (CODX) on Behalf of Investors
- 06/18/2020
|
ROSEN, A LONGSTANDING AND LEADING FIRM, Announces Securities Class Action Lawsuit Against Co-Diagnostics, Inc. Seeking Recovery of Investor Losses- CODX
- NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Rosen Law Firm, a global investor rights law firm, announces the filing of a class-action lawsuit on behalf of purchasers of the securities of Co-Diagnostics, ...
- 06/18/2020
|
Securities Class Action Lawsuit Filed Against COVID-19 test maker, Co-Diagnostics, Inc. by Marcus Neiman Rashbaum & Pineiro, LLP, Smith Washburn, LLP, and Fasano Law Firm, PLLC
- Marcus Neiman Rashbaum & Pineiro, LLP, Smith Washburn, LLP, and Fasano Law Firm, PLLC announce they have filed a class action lawsuit (Case 2:20-cv-00368-CMR) in the United States District Court, District of Utah, Central Division on behalf of purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the "Class Period").
- 06/18/2020
|
CODX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or ...
- 06/18/2020
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Co-Diagnostics, Inc. (CODX) on Behalf of Investors
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Co-Diagnostics, Inc. (CODX) on Behalf of Investors
- 06/18/2020
|
Shareholder Alert: Robbins LLP Announces Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders
- Shareholder rights law firm Robbins LLP announces that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Co
- 06/18/2020
|
